Press release
Obesity Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Obesity Overview
Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body
"Obesity Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.
The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Obesity Pipeline Report: https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. Obesity Key players such as - D&D Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment
• Obesity Emerging therapies such as - DD03, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.
• In February 2022, Carmot Therapeutics initiated a randomized, double-blind, placebo-controlled, parallel-group, multiple-center study to evaluate the efficacy, safety, and tolerability of CT-868 administered for 26 weeks to overweight andobese participants with Type 2 diabetes mellitus
• In October 2022, Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the investigation of tirzepatide for the treatment of adults with obesity or overweight with weight-related comorbidities
• In April 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled, Phase III study comparing the efficacy and safety of Tirzepatide vs. placebo in patients with heart failure with preserved ejection fraction and obesity (SUMMIT)
• In May 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of once-weekly Tirzepatide in participants with obesity disease
Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Obesity Pipeline Therapeutics Assessment
• Obesity Assessment by Product Type
• Obesity By Stage and Product Type
• Obesity Assessment by Route of Administration
• Obesity By Stage and Route of Administration
• Obesity Assessment by Molecule Type
• Obesity by Stage and Molecule Type
DelveInsight's Obesity Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Obesity Therapeutics Market include:
Key companies developing therapies for Obesity are - ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others.
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
• DD03: D&D Pharmatech
• CBW-520: Caliway Biopharmaceutics
• NPM 139: Nano Precision Medical
• BK-1701: Bukwang Pharmaceutical
• YH34160: Yuhan
• TNX-2900: Tonix Pharmaceuticals
• Thermostem: BioRestorative Therapies
• SCO-267: SCOHIA PHARMA
• CT-181: Click Therapeutics
• HM15136: Hanmi Pharmaceuticals
• NNC0480-0389: Novo Nordisk
• XW003: Sciwind Biosciences
• EMP-16: Empros Pharma
• CT-868: Carmot Therapeutics
• Tirzepatide: Eli Lilly and Company
• Semaglutide: Oral Novo Nordisk
Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies at:
https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Obesity Pipeline Market Drivers
• Rise in prevalence of Obesity
• Growing Research and Development Activities to develop novel therapies to treat obesity
• Changing lifestyle patterns
Obesity Pipeline Market Barriers
• Challenges associated with the discovery of anti-obesity drugs
• Economic burden associated with obesity
Scope of Obesity Pipeline Drug Insight
• Coverage: Global
• Key Obesity Companies: D&D Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others
• Key Obesity Therapies: DD03, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Obesity Report Introduction
2 Obesity Executive Summary
3 Obesity Overview
4 Obesity- Analytical Perspective In-depth Commercial Assessment
5 Obesity Pipeline Therapeutics
6 Obesity Late Stage Products (Phase II/III)
7 Obesity Mid Stage Products (Phase II)
8 Obesity Early Stage Products (Phase I)
9 Obesity Preclinical Stage Products
10 Obesity Therapeutics Assessment
11 Obesity Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Obesity Key Companies
14 Obesity Key Products
15 Obesity Unmet Needs
16 Obesity Market Drivers and Barriers
17 Obesity Future Perspectives and Conclusion
18 Obesity Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Obesity drugs and therapies- https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Obesity Market https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Obesity-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2957933 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Obesity
Anti-Obesity Drugs Market Grows Rapidly, Driven by Obesity Rates and Therapeutic …
Anti-Obesity Drugs Market valued at USD 5.9 Bn in 2024, growing at 16.5% CAGR to reach USD 20.02 Bn by 2032. Driven by GLP-1 therapies and rising obesity rates.
Anti Obesity Drugs Market Overview:
The anti-obesity drugs market is undergoing significant transformation as awareness about obesity-related health risks rises globally. With growing concern over lifestyle-related disorders, there is an increasing emphasis on medical intervention as a complement to traditional weight management strategies.…
Fuzzle joins The Obesity Society & The Obesity Action Coalition; Promotes Habit- …
Building healthy, sustainable habits for long-term weight management success.
Tampa, FL - March 18, 2025 - Fuzzle, an emerging leader in the wellness landscape, is pleased to announce that it's now a Member of The Obesity Society, as well as the Obesity Action Coalition, marking a new milestone in the company's mission to transform how individuals approach weight loss.
Image: https://www.globalnewslines.com/uploads/2025/03/77da787ae98a633847c70fc22e2943c7.jpg
Fuzzle supports individuals in their wellness journey through non-invasive, drug-free strategies. With…
Pediatric Obesity Management Market - Healthy Habits for Life: Advancing Pediatr …
Newark, New Castle, USA: The "Pediatric Obesity Management Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Pediatric Obesity Management Market: https://www.growthplusreports.com/report/pediatric-obesity-management-market/8930
This latest report researches the industry structure,…
Anti-Obesity Drugs Market - From Obesity to Vitality: Leading the Way in Effecti …
Newark, New Castle, USA - new report, titled Anti-Obesity Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-Obesity Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-Obesity Drugs market. The report offers an overview of the market, which…
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle…
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close…
